---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-001952"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:15:15.560640+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics raises $135M in oversubscribed private placement to fund CNTY-813 T1D program

## Summary
- Gross proceeds ~$135M; 117.4M shares/pre-funded warrants + 58.7M warrants at $1.15 per unit.
- Led by new investor TCGX; includes RA Capital, Commodore, Deep Track, RTW, Venrock, T1D Fund.
- Proceeds fund lead candidate CNTY-813 (beta islet cell for T1D); cash runway extended to Q1 2029.
- IND submission for CNTY-813 expected in 2026; initial clinical data anticipated in 2027.
- Full exercise of warrants could yield additional ~$153M at $2.60 per share.

## SEC filing metadata
- accession: 0001104659-26-001952
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/0001104659-26-001952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/tm262422d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-001952
- JSON: https://secwatch.observer/filing/0001104659-26-001952.json
- Plain text: https://secwatch.observer/filing/0001104659-26-001952.txt

## Key facts
- Material Agreements
  Century Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $135.0 million (effective 2026-01-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Value: approximately $135.0 million
  - Effective: 2026-01-07
  source text: On January 7, 2026, Century Therapeutics, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (a) (i) 92,030,595 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, and/or, (ii) pre-funded warrants to purchase 25,360,704 shares of Common Stock (“Pre-Funded Warrants”) and (b) warrants to purchase 58,695,648 shares of Common Stock or Pre-Funded Warrants in lieu thereof (“Common Warrants”, together with the Pre-Funded Warrants, the “Warrants”) at a purchase price of $1.15 per share and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant and a purchase price of $1.1499 per Pre-Funded Warrant and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant (the “Private Placemen
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/0001104659-26-001952-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.